Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 16481659)

1.

The NIMH-MATRICS consensus statement on negative symptoms.

Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR.

Schizophr Bull. 2006 Apr;32(2):214-9. Epub 2006 Feb 15. No abstract available.

2.

The MATRICS consensus cognitive battery: what we know 6 years later.

Green MF, Harris JG, Nuechterlein KH.

Am J Psychiatry. 2014 Nov 1;171(11):1151-4. doi: 10.1176/appi.ajp.2014.14070936. No abstract available.

PMID:
25756630
3.

The 2010 Institute of Medicine consensus statement "A national clinical trials network for the 21st century": progress and challenges.

Mendelsohn J, Bertagnolli MM.

Semin Oncol. 2014 Aug;41(4):435-6. doi: 10.1053/j.seminoncol.2014.06.003. Epub 2014 Jun 11. No abstract available.

PMID:
25173135
4.

Studying hallucinations within the NIMH RDoC framework.

Ford JM, Morris SE, Hoffman RE, Sommer I, Waters F, McCarthy-Jones S, Thoma RJ, Turner JA, Keedy SK, Badcock JC, Cuthbert BN.

Schizophr Bull. 2014 Jul;40 Suppl 4:S295-304. doi: 10.1093/schbul/sbu011. Epub 2014 May 21. Review.

5.

National Institute of Mental Health clinical trials: new opportunities, new expectations.

Insel TR, Gogtay N.

JAMA Psychiatry. 2014 Jul 1;71(7):745-6. doi: 10.1001/jamapsychiatry.2014.426. No abstract available.

PMID:
24806613
6.

Mental health: More than neurobiology.

Fried E, Tuerlinckx F, Borsboom D.

Nature. 2014 Apr 24;508(7497):458. doi: 10.1038/508458c. No abstract available.

PMID:
24759405
7.

Perspective: Retreat from the radical.

Marder SR.

Nature. 2014 Apr 3;508(7494):S18. doi: 10.1038/508S18a. No abstract available.

PMID:
24695331
8.

Hitting the target: a new framework for mental health trials.

[No authors listed]

Lancet. 2014 Mar 15;383(9921):928. doi: 10.1016/S0140-6736(14)60465-7. No abstract available.

PMID:
24629280
9.

Clinical trials for negative symptoms--emerging directions and unresolved issues.

Marder SR, Rabinowitz J, Kapur S.

Schizophr Res. 2013 Nov;150(2-3):327. doi: 10.1016/j.schres.2013.10.005. No abstract available.

PMID:
24209763
10.

Adapting social neuroscience measures for schizophrenia clinical trials, Part 1: ferrying paradigms across perilous waters.

Green MF, Lee J, Ochsner KN.

Schizophr Bull. 2013 Nov;39(6):1192-200. doi: 10.1093/schbul/sbt131. Epub 2013 Sep 26.

11.

[Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].

Rodríguez-Jiménez R, Bagney A, Moreno-Ortega M, García-Navarro C, Aparicio AI, López-Antón R, de la Oliva J, Jiménez-Arriero MÁ, Santos JL, Lobo A, Palomo T.

Rev Neurol. 2012 Nov 1;55(9):549-55. Review. Spanish.

12.

The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.

Rodriguez-Jimenez R, Bagney A, Garcia-Navarro C, Aparicio AI, Lopez-Anton R, Moreno-Ortega M, Jimenez-Arriero MA, Santos JL, Lobo A, Kern RS, Green MF, Nuechterlein KH, Palomo T.

Schizophr Res. 2012 Feb;134(2-3):279-84. doi: 10.1016/j.schres.2011.11.026. Epub 2011 Dec 20.

PMID:
22192501
13.

The NIMH-CATIE Schizophrenia Study: what did we learn?

Lieberman JA, Stroup TS.

Am J Psychiatry. 2011 Aug;168(8):770-5. doi: 10.1176/appi.ajp.2011.11010039. No abstract available.

PMID:
21813492
14.

Schizophrenia treatment guidelines in the United States.

Moore TA.

Clin Schizophr Relat Psychoses. 2011 Apr;5(1):40-9. doi: 10.3371/CSRP.5.1.6. Review.

PMID:
21459738
15.

Implementing treatment guidelines.

Miller AL.

Clin Schizophr Relat Psychoses. 2011 Apr;5(1):15-6. doi: 10.3371/CSRP.5.1.2. No abstract available.

PMID:
21459734
16.

Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.

Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A.

Schizophr Res. 2011 Feb;125(2-3):161-8. doi: 10.1016/j.schres.2010.09.015. Epub 2010 Dec 31.

PMID:
21075600
17.

NIMH-funded pragmatic trials: moving on.

Wang PS, Insel TR.

Neuropsychopharmacology. 2010 Dec;35(13):2489-90. doi: 10.1038/npp.2010.161. No abstract available.

18.

A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials.

Schennach-Wolff R, Möller HJ, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Riedel M.

Pharmacopsychiatry. 2010 Nov;43(7):245-51. doi: 10.1055/s-0030-1262788. Epub 2010 Oct 6.

PMID:
20927697
19.

What have we learned about trial design from NIMH-funded pragmatic trials?

March J, Kraemer HC, Trivedi M, Csernansky J, Davis J, Ketter TA, Glick ID.

Neuropsychopharmacology. 2010 Dec;35(13):2491-501. doi: 10.1038/npp.2010.115. Epub 2010 Aug 25.

20.

The brief negative symptom scale: psychometric properties.

Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR.

Schizophr Bull. 2011 Mar;37(2):300-5. doi: 10.1093/schbul/sbq059. Epub 2010 Jun 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk